4MKC

Crystal Structure of Anaplastic Lymphoma Kinase Complexed with LDK378


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.01 Å
  • R-Value Free: 0.218 
  • R-Value Work: 0.171 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer.

Friboulet, L.Li, N.Katayama, R.Lee, C.C.Gainor, J.F.Crystal, A.S.Michellys, P.Y.Awad, M.M.Yanagitani, N.Kim, S.Pferdekamper, A.C.Li, J.Kasibhatla, S.Sun, F.Sun, X.Hua, S.McNamara, P.Mahmood, S.Lockerman, E.L.Fujita, N.Nishio, M.Harris, J.L.Shaw, A.T.Engelman, J.A.

(2014) Cancer Discov 4: 662-673

  • DOI: 10.1158/2159-8290.CD-13-0846

  • PubMed Abstract: 
  • Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib. Herein, we report the first preclinical evaluation of the next-gen ...

    Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib. Herein, we report the first preclinical evaluation of the next-generation ALK TKI, ceritinib (LDK378), in the setting of crizotinib resistance. An interrogation of in vitro and in vivo models of acquired resistance to crizotinib, including cell lines established from biopsies of patients with crizotinib-resistant NSCLC, revealed that ceritinib potently overcomes crizotinib-resistant mutations. In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, I1171T, and S1206Y mutations, and a cocrystal structure of ceritinib bound to ALK provides structural bases for this increased potency. However, we observed that ceritinib did not overcome two crizotinib-resistant ALK mutations, G1202R and F1174C, and one of these mutations was identified in 5 of 11 biopsies from patients with acquired resistance to ceritinib. Altogether, our results demonstrate that ceritinib can overcome crizotinib resistance, consistent with clinical data showing marked efficacy of ceritinib in patients with crizotinib-resistant disease.


    Organizational Affiliation

    Genomics Institute of the Novartis Research Foundation, San Diego, CA 92121.,Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.,Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA.,Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JAPAN.,Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, JAPAN.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
ALK tyrosine kinase receptor
A
367Homo sapiensMutation(s): 1 
Gene Names: ALK
EC: 2.7.10.1
Find proteins for Q9UM73 (Homo sapiens)
Go to Gene View: ALK
Go to UniProtKB:  Q9UM73
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
GOL
Query on GOL

Download SDF File 
Download CCD File 
A
GLYCEROL
GLYCERIN; PROPANE-1,2,3-TRIOL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
 Ligand Interaction
4MK
Query on 4MK

Download SDF File 
Download CCD File 
A
5-chloro-N~2~-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-N~4~-[2-(propan-2-ylsulfonyl)phenyl]pyrimidine-2,4-diamine
Ceritinib, LDK378
C28 H36 Cl N5 O3 S
VERWOWGGCGHDQE-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
4MKIC50: 0.2 - 41 nM (99) BINDINGDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.01 Å
  • R-Value Free: 0.218 
  • R-Value Work: 0.171 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 51.640α = 90.00
b = 57.650β = 90.00
c = 105.990γ = 90.00
Software Package:
Software NamePurpose
DENZOdata reduction
BUSTERrefinement
HKL-2000data collection
SCALEPACKdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2014-04-09
    Type: Initial release
  • Version 1.1: 2014-06-18
    Type: Database references
  • Version 1.2: 2015-04-29
    Type: Non-polymer description